BioSpace News Archive

Third Pole Therapeutics , a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today that it has entered into a $15 million debt facility with Avenue Venture Opportunities Fund, L.P. (“Avenue Venture Fund”).

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the results from the Company’s preclinical studies of its targeted cancer immunotherapeutic agent will be presented as a poster at the New York Academy of Science’s (NYAS) Frontiers in Cancer Immunotherapy Symposium 2021.

Presentations include data highlighting real-world use of RECELL in combination with complementary treatments, clinical versatility, and cost effectiveness of RECELL to advance patient care

AltruBio Inc., a clinical stage biotech company, has announced the completion of a $63 million Series A financing round.

A recent study of patients receiving oral FDA-approved therapies used to treat relapsing forms of multiple sclerosis (MS) revealed high tolerance, low rates of adverse drug events, and similar medication adherence rates across all study medications.

Grant will work to mobilize and engage Black Americans in cancer risk reduction and contribute to ACS’ mortality goal of reducing cancer death by 40% by 2035

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has launched a new line of high capacity controlled rate freezers (HCRF), with an initial shipment to a leading cell therapy company.

NanoView Biosciences Inc. (“NanoView”), a leading biomarker characterization company in the emerging field of extracellular vesicle biology, today announced a collaboration agreement with Beth Israel Deaconess Medical Center (“BIDMC”) to study the involvement of biomarkers

InterVenn Biosciences today announced that Nobel Prize recipient, James P. Allison, has joined the company’s Board of Advisors, effective March 9, 2021. Dr. Allison joins the InterVenn Board of Advisors with over 45 years of experience in Immunology and cancer research.

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced two posters will be presented at the American Academy of Neurology (AAN) 73rd Annual Meeting